Effect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer

被引:6
作者
Wu, C. [1 ]
Wang, T. [1 ]
Wang, J. [1 ]
Qu, B. [1 ]
Wang, H. [1 ]
Hu, Y. [1 ]
机构
[1] Peoples Liberat Army, Gen Hosp, Dept Oncol, Beijing, Peoples R China
关键词
Small cell lung cancer; Extensive stage; Radiotherapy; PROPHYLACTIC CRANIAL IRRADIATION; PHASE-III TRIAL; THORACIC RADIOTHERAPY; CHEMOTHERAPY; CISPLATIN; RADIATION; ETOPOSIDE; ETOPOSIDE/CISPLATIN; METAANALYSIS; COMBINATION;
D O I
10.4238/2014.January.24.7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Small cell lung cancer (SCLC) is an aggressive disease, in which more than 80% of patients present distant metastases at the time of first diagnosis. Chemotherapy is considered as the main treatment of extensive disease of SCLC (ED-SCLC), while the role of radiotherapy in the treatment of ED-SCLC is controversial. A case-control study was undertaken of patients diagnosed as ED-SCLC between 2004 and 2010. Fifty-eight patients with overall survival (OS) over 1 year were chosen, and another 58 patients with OS less than 1 year were selected as the control group, with the age, gender, metastasis or no metastasis of the liver, and the response after the first line of chemotherapy matched. The 1-year, 2-year, 3-year, and median OS of the 75 ED-SCLC patients who received radiation were 81.47, 29.89, 22.77%, and 17 months, respectively, and were 61.18, 23.53, 0%, and 16 months, respectively, for patients who did not receive radiation. The chi(2) test and odds ratio (OR) estimate demonstrated that these differences were statistically significant (chi(2) = 6.38, P = 0.0116; OR = 2.74, 95% confidence interval = 1.24-6.05). These results show that radiotherapy also plays a role in responding patients with extensive stage of SCLC.
引用
收藏
页码:8577 / 8585
页数:9
相关论文
共 20 条
[1]   PROPHYLACTIC CRANIAL IRRADIATION FOR PATIENTS WITH SMALL-CELL LUNG-CANCER IN COMPLETE REMISSION [J].
ARRIAGADA, R ;
LECHEVALIER, T ;
BORIE, F ;
RIVIERE, A ;
CHOMY, P ;
MONNET, I ;
TARDIVON, A ;
VIADER, F ;
TARAYRE, M ;
BENHAMOU, S .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (03) :183-190
[2]   Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure? [J].
Brade, AM ;
Tannock, IF .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1020-1022
[3]   In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells [J].
Combs, Stephanie E. ;
Zipp, Lisa ;
Rieken, Stefan ;
Habermehl, Daniel ;
Brons, Stefan ;
Winter, Marcus ;
Haberer, Thomas ;
Debus, Juergen ;
Weber, Klaus-Josef .
RADIATION ONCOLOGY, 2012, 7
[4]   Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].
De Ruysscher, D ;
Pijls-Johannesma, M ;
Bentzen, SM ;
Minken, A ;
Wanders, R ;
Lutgens, L ;
Hochstenbag, M ;
Boersma, L ;
Wouters, B ;
Lammering, G ;
Vansteenkiste, J ;
Lambin, P .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063
[5]   Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer [J].
Eckardt, JR ;
von Pawel, J ;
Papai, Z ;
Tomova, A ;
Tzekova, V ;
Crofts, TE ;
Brannon, S ;
Wissel, P ;
Ross, G .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2044-2051
[6]   Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database [J].
Govindan, Ramaswamy ;
Page, Nathan ;
Morgensztern, Daniel ;
Read, William ;
Tierney, Ryan ;
Vlahiotis, Anna ;
Spitznagel, Edward L. ;
Piccirillo, Jay .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4539-4544
[7]   Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): Final results of a randomised phase III trial [J].
Heigener, D. F. ;
Freitag, L. ;
Eschbach, C. ;
Huber, R. M. ;
Fink, T. ;
Hummler, S. ;
Banik, N. ;
Wolf, M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[8]   Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study [J].
Jeremic, B ;
Shibamoto, Y ;
Nikolic, N ;
Milicic, B ;
Milisavljevic, S ;
Dagovic, A ;
Aleksandrovic, J ;
Radosavljevic-Asic, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2092-2099
[9]   Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results [J].
Komatsu, Tetsuya ;
Oizumi, Yukio ;
Kunieda, Etsuo ;
Tamai, Yoshifumi ;
Akiba, Takeshi ;
Kogawa, Asuka .
ONCOLOGY LETTERS, 2011, 2 (05) :855-860
[10]   Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124 [J].
Lara, Primo N., Jr. ;
Natale, Ronald ;
Crowley, John ;
Lenz, Heinz Josef ;
Redman, Mary W. ;
Carleton, Jane E. ;
Jett, James ;
Langer, Corey J. ;
Kuebler, J. Philip ;
Dakhil, Shaker R. ;
Chansky, Kari ;
Gandara, David R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2530-2535